AbbVie to Buy Cerevel Therapeutics for $8.7 Billion
- December 08, 2023
AbbVie Inc. is looking to bolster its neuroscience pipeline with a bid to acquire Cerevel Therapeutics in a transaction valued at roughly $8.7 million, the companies announced December 7.
ARTICLE TAGS
You must be logged in to access this content.